secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-09-22T11:08:41+00:00
Accession:  0001193125-26-397221
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo to acquire Mantle for up to $21.3M; adds FA pipeline and collaborations
-----------------------------------------------------------------------------

- Acquisition: $8.3M upfront (cash+equity) plus up to $13M milestones for Mantle; total potential $21.3M; close expected Q3 2026.
- Mantle pipeline adds LX3010 (oral, ~6-pt mFARS improvement, 9x frataxin increase), LX3030, LX3050, LX3070 for FA.
- Collaborations: Weill Cornell (cerebellar sequential dosing), Vivet (VTX-PID option), Apertura (CapX capsid option) to support LX2006.
- LX2006 SUNRISE-FA 2 topline on track for 2H 2027; CLARITY-FA has 22 participants enrolled/imminently enrolling.
- Cash runway into 2028 unchanged; expects to advance one acquired program to clinic and submit an IND in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/0001193125-26-397221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-20260916.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-397221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer